Home

Articles from Eolas Therapeutics, Inc.

Eolas Therapeutics Secures Full Development Rights to AZD4041
Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an investigational therapy targeting the orexin-1 receptor, for the treatment of opioid use disorder (OUD) and other substance use disorders. Terms of the agreement are confidential.
By Eolas Therapeutics, Inc. · Via Business Wire · July 10, 2025